Boston Common Asset Management LLC grew its position in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 29.4% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 24,028 shares of the company's stock after acquiring an additional 5,465 shares during the quarter. Boston Common Asset Management LLC's holdings in Eli Lilly and Company were worth $18,550,000 as of its most recent filing with the SEC.
Several other hedge funds and other institutional investors also recently modified their holdings of LLY. Beck Bode LLC bought a new stake in shares of Eli Lilly and Company during the second quarter valued at about $15,036,000. XTX Topco Ltd bought a new stake in shares of Eli Lilly and Company during the second quarter valued at about $546,000. Benjamin F. Edwards & Company Inc. raised its stake in shares of Eli Lilly and Company by 3.3% during the second quarter. Benjamin F. Edwards & Company Inc. now owns 8,723 shares of the company's stock valued at $7,898,000 after purchasing an additional 276 shares in the last quarter. Pacer Advisors Inc. raised its stake in shares of Eli Lilly and Company by 5.8% during the second quarter. Pacer Advisors Inc. now owns 68,017 shares of the company's stock valued at $61,581,000 after purchasing an additional 3,713 shares in the last quarter. Finally, Garden State Investment Advisory Services LLC raised its stake in shares of Eli Lilly and Company by 14.8% during the second quarter. Garden State Investment Advisory Services LLC now owns 2,262 shares of the company's stock valued at $2,052,000 after purchasing an additional 291 shares in the last quarter. Institutional investors and hedge funds own 82.53% of the company's stock.
A number of brokerages recently weighed in on LLY. Sanford C. Bernstein assumed coverage on shares of Eli Lilly and Company in a research note on Thursday, October 17th. They set an "outperform" rating and a $1,100.00 price objective on the stock. Wolfe Research assumed coverage on shares of Eli Lilly and Company in a research report on Friday, November 15th. They issued an "outperform" rating and a $1,000.00 price target on the stock. Deutsche Bank Aktiengesellschaft dropped their price target on shares of Eli Lilly and Company from $1,025.00 to $1,015.00 and set a "buy" rating on the stock in a research report on Monday, November 4th. StockNews.com upgraded shares of Eli Lilly and Company from a "hold" rating to a "buy" rating in a research report on Wednesday, January 1st. Finally, Truist Financial boosted their price target on shares of Eli Lilly and Company from $1,000.00 to $1,033.00 and gave the stock a "buy" rating in a research report on Thursday, October 10th. Four research analysts have rated the stock with a hold rating and eighteen have given a buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $1,002.22.
Check Out Our Latest Report on Eli Lilly and Company
In related news, CAO Donald A. Zakrowski sold 900 shares of the business's stock in a transaction that occurred on Friday, November 8th. The stock was sold at an average price of $803.38, for a total value of $723,042.00. Following the completion of the sale, the chief accounting officer now owns 5,480 shares of the company's stock, valued at approximately $4,402,522.40. The trade was a 14.11 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. 0.13% of the stock is currently owned by company insiders.
NYSE:LLY opened at $726.24 on Friday. The company has a debt-to-equity ratio of 2.03, a current ratio of 1.27 and a quick ratio of 0.97. Eli Lilly and Company has a fifty-two week low of $612.70 and a fifty-two week high of $972.53. The stock's 50-day moving average is $781.14 and its two-hundred day moving average is $854.71. The stock has a market cap of $689.43 billion, a PE ratio of 78.51, a price-to-earnings-growth ratio of 1.66 and a beta of 0.41.
Eli Lilly and Company (NYSE:LLY - Get Free Report) last released its earnings results on Wednesday, October 30th. The company reported $1.18 earnings per share for the quarter, missing the consensus estimate of $1.52 by ($0.34). Eli Lilly and Company had a net margin of 20.48% and a return on equity of 71.08%. The business had revenue of $11.44 billion for the quarter, compared to analysts' expectations of $12.09 billion. During the same period last year, the firm earned $0.10 EPS. The company's revenue was up 20.4% compared to the same quarter last year. As a group, equities research analysts forecast that Eli Lilly and Company will post 13.14 earnings per share for the current fiscal year.
The firm also recently announced a quarterly dividend, which will be paid on Monday, March 10th. Shareholders of record on Friday, February 14th will be paid a dividend of $1.50 per share. This represents a $6.00 annualized dividend and a yield of 0.83%. The ex-dividend date of this dividend is Friday, February 14th. This is a boost from Eli Lilly and Company's previous quarterly dividend of $1.30. Eli Lilly and Company's payout ratio is 56.22%.
Eli Lilly and Company announced that its Board of Directors has approved a stock buyback plan on Monday, December 9th that permits the company to repurchase $15.00 billion in shares. This repurchase authorization permits the company to buy up to 2% of its shares through open market purchases. Shares repurchase plans are generally an indication that the company's board believes its stock is undervalued.
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider Eli Lilly and Company, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Eli Lilly and Company wasn't on the list.
While Eli Lilly and Company currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.